Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia

Alzheimer Disease Clinical Trial

Official title:

Investigations of Naproxen Treatment Effects in Pre-clinical Alzheimer's Disease (INTREPAD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02702817
• Other study ID #: INTREPAD
• Status: Completed
• Phase: Phase 2
• First received: December 19, 2015
• Last updated: July 29, 2017
• Start date: August 1, 2012
• Est. completion date: July 15, 2017

Study information

• Verified date: July 2017
• Source: Douglas Mental Health University Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Two-year double-masked trial of over-the-counter dosage of naproxen sodium vs placebo in 200 cognitively normal participants with a parental or multiplex first-degree family history Alzheimer's disease (AD) dementia. Primary outcomes are decline in cognitive function and slope of change in a summary Alzheimer Progression Score derived from serial assessment of neuroimaging, biochemical, and sensori-neural biomarker indicators of pre-clinical disease -- all believed likely to reflect progress of preclinical AD in this high risk cohort. Approximately 2/3 of participants have volunteered also for serial lumbar punctures for analysis of cerebrospinal fluid. A two-year off-treatment delayed-washout phase is planned to examine sustained treatment effects and evidence of disease modification.

Description:

The trial enrolled 195 cognitively normal persons aged 60+ with either a parental history of AD or a history of two or more affected first-degree relatives. Persons aged 55-59 were admitted if their current age was <= 15 years younger than AD onset in their index relative. Such persons are believed to be at approximately 3-fold increased risk of AD dementia. We expected a majority of them to show evidence of progressive pre-clinical AD. Participants were randomized 1:1 to receive the common non-steroidal anti-inflammatory drug (NSAID) naproxen in over-the-counter dosage (naproxen sodium 220 mg) or identical-appearing placebo tablets twice daily. At baseline and at three follow-up visits (3 months, 12 months and 24 months after randomization) they were tested for cognitive abilities and undergo brain imaging with both structural and functional MRI. They are also tested for sensori-neural capacities in olfactory identification and in the ability to discern spoken language in a distracting environment (to test central auditory processing). About 2/3 of participants also volunteered to undergo a series of lumbar punctures for donation of cerebrospinal fluid (CSF), which was assayed for several biochemical markers of AD that are now understood to be present for a decade or longer before the onset of symptoms. As well, their plasma and CSF are assayed for presence of naproxen and for numerous markers of inflammatory processes (cytokines and chemokines). The central hypothesis was that administration of naproxen would not only suppress these inflammatory markers but would also slow or reverse the progress of change in cognition and in biomarkers of the pre-clinical stage of AD. The analysis plan followed the principle of modified Intent-to-Treat, considering outcomes for all persons who had at least one follow-up examination while on-protocol. After completion of two years of treatment, these participants are being followed for a further two years to observe whether treatment-related changes are sustained -- indicating that the treatment effects represent modification of the disease process itself, as opposed to a temporary change in brain function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: July 15, 2017
• Est. primary completion date: March 31, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• good physical health including normal hemoglobin and hematocrit

• history or documentation of AD dementia in at least one parent, or in two siblings

• cognitive performance without diagnosable deficit such as dementia, "mild cognitive impairment"

• must have spouse or companion able to accompany participant for clinic visits

• six or more years of formal education

• fluent in either English or French

• provision of informed consent

Exclusion Criteria:

• no current peptic ulcer disease

• no history of prior peptic ulcer with bleed, perforation, intestinal obstruction

• no major psychiatric disturbance

• no regular use (4 or more doses per week) of aspirin, other non-steroidal anti-inflammatory drug (NSAID), opiate or other pain medication

• no use, present or past, of acetylcholinesterase inhibitors or memantine

• no regular use of vitamin E at dosage of 600 i.u.

• no drug or alcohol dependence

• no allergy to NSAIDs or sulfa antibiotics

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognition Disorders
• Cognitive Decline Due to Alzheimer Disease
• Mild Cognitive Impairment
• Mild Cognitive Impairment Due to Alzheimer Disease

Intervention

Drug:
• Naproxen
pale blue oval tablets
• Placebo
pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention

Locations

Country	Name	City	State
Canada	Douglas Hospital Research Centre	Montreal	Quebec

Sponsors (3)

Lead Sponsor	Collaborator
Douglas Mental Health University Institute	Johns Hopkins University, McGill University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease	Summary score derived using latent trait Item Response Theory analyses, trajectory estimated from mixed effects models based on multiple individual markers observed at baseline, three months, 12 months, and 24 months following randomization	Two years for primary outcome, with intent to follow participants off-treatment for two-year observational delayed washout
Secondary	frequency and severity of treatment-emergent adverse events	classified by organ system involvement and need for treatment interruption or cessation.	collected in real-time over two years following RZ
Secondary	trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status	global score of primary interest, although individual scale scores will be used in secondary analyses	observed at baseline, annually thereafter over two years following randomization (RZ), and two years further (delayed washout)
Secondary	ratio of total and protein-bound naproxen concentrations as well as kinetics of drug accumulation and washout	estimate of blood brain barrier permeability and rapidity of drug accumulation and washout in both plasma and CSF partitions	estimated at three months and annually thereafter for two years following RZ, with further two years delayed washout
Secondary	biomarkers of inflammatory processes	quantitative measures of 44 different inflammatory cytokines measured in plasma, and in CSF when available	measured at three months and annually thereafter for two years following RZ, with further two years delayed washout
Secondary	CSF biomarkers of AD pathogenesis	concentrations of total tau protein, phosphorylated tau protein, Amyloid beta 1-40 and Amyloid beta 1-42, apolipoprotein E	observed at baseline, after three months, and annually thereafter over two years following randomization (RZ), and two years thereafter off-treatment (delayed washout)